France DNA vaccine market was valued at $34.70 million in 2025 and is projected to reach $52.18 million by 2035, registering a CAGR of 4.3% during the forecast period from 2026 to 2035. The market is being propelled by a sustained expansion of research and development activity focused on next-generation vaccine platforms. A comprehensive government-published innovation report indicates that France had 145 vaccines under development as part of its national pipeline in 2025, with a measurable share attributed to DNA vaccine programs among advanced technology categories. This robust pipeline underscores the country’s strategic focus on diversifying vaccine technologies beyond traditional types, reinforcing academic–industry collaboration and reinforcing commercial interest. The concentration of vaccine R&D efforts, including DNA-based approaches, is improving clinical readiness and attracting investment into plasmid DNA development and delivery technologies. As a result, the market is benefiting from increased scientific activity that strengthens long-term technological capacity and supports future commercial launches.
Browse the full report description of “France DNA Vaccine Market Size, Share & Trends Analysis Report by Type (Animal DNA Vaccine, and Human DNA Vaccine), by Technology (Plasmid DNA Vaccines Technology, and Plasmid DNA Delivery Technology), by Application (Oncology, Infectious Diseases, and Others), Forecast Period 2026-2035” at https://www.omrglobal.com/industry-reports/france-dna-vaccines-market
According to the latest official French government innovation report on vaccines under development, France had 145 vaccine products in the development pipeline in its R&D ecosystem as of 2025. Of these, a portion is associated with novel platform technologies such as DNA vaccines alongside mRNA and vector-based platforms, reflecting diversification within the national vaccine portfolio. The report notes that France hosts multiple CDMOs with vaccine expertise and a balanced distribution across development phases from preclinical to Phase III, indicating active progression of candidates. This expanded pipeline positions DNA vaccine technology as a contributor to national health innovation strategies and offers comparative advantage in infectious disease preparedness.
Market Coverage
Key questions addressed by the report.
France DNA Vaccine Market Report Segment
By Type
By Technology
By Application
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/france-dna-vaccines-market